337 related articles for article (PubMed ID: 24200614)
1. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
Takao M
Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
3. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Keene DL; Legare C; Taylor E; Gallivan J; Cawthorn GM; Vu D
Can J Neurol Sci; 2011 Jul; 38(4):565-71. PubMed ID: 21672696
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
6. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
8. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
9. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
12. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis, natalizumab, and PML: helping patients decide.
Rudick RA
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
[TBL] [Abstract][Full Text] [Related]
15. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
Stüve O; Marra CM; Cravens PD; Singh MP; Hu W; Lovett-Racke A; Monson NL; Phillips JT; Tervaert JW; Nash RA; Hartung HP; Kieseier BC; Racke MM; Frohman EM; Hemmer B
Arch Neurol; 2007 Feb; 64(2):169-76. PubMed ID: 17296831
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
17. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
18. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
19. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
[TBL] [Abstract][Full Text] [Related]
20. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
Calvi A; De Riz M; Pietroboni AM; Ghezzi L; Maltese V; Arighi A; Fumagalli GG; Jacini F; Donelli C; Comi G; Galimberti D; Scarpini E
Immunotherapy; 2014; 6(1):23-8. PubMed ID: 24341880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]